Skip to main navigation Skip to search Skip to main content

Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022

  • Megan V.C. Barnes
  • , Anika Mandla
  • , Emma Smith
  • , Maija Maskuniitty
  • , Peter J.M. Openshaw
  • , Yara Natalie Abo
  • , Stephanie Ascough
  • , Helen Ashwin
  • , Panisadee Avirutnan
  • , Andrew P. Catchpole
  • , Primus Che Chi
  • , Christopher Chiu
  • , Thomas C. Darton
  • , Emmanuella Driciru
  • , Dingase Dula
  • , Daniela Ferreira
  • , Alastair Fraser
  • , Phoebe Garrett
  • , Diane Gbesemete
  • , Stephen Gordon
  • David L. Heymann, Emma Houlder, Euzebiusz Jamrozik, Melissa Kapulu, Enock Kessy, Anna M. Overgaard Kildemoes, Jan Pieter Koopman, Helen McShane, Oranich Navanukroh, Faith H. Osier, Joshua Osowicki, Vy Pham, Andrew J. Pollard, Woraphat Ratta-Apha, Sarah E. Silk, Saranya Sridhar, Kena A. Swanson, Kawsar R. Talaat, Ryan S. Thwaites, Orly Welch
  • Imperial College London
  • Royal Children's Hospital
  • University of York
  • Mahidol University
  • hVIVO
  • KEMRI-Wellcome Trust Research Programme
  • University of Sheffield
  • Leiden University
  • Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • University of Oxford
  • 1Day Sooner
  • University of Southampton
  • London School of Hygiene and Tropical Medicine
  • Ifakara Health Institute
  • University of Melbourne
  • Sanofi Pasteur and Inno4Vac
  • Pfizer
  • Johns Hopkins University

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.
Original languageEnglish
Article numberltad024
JournalImmunotherapy Advances
Volume3
Issue number1
DOIs
Publication statusPublished - 31 Oct 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • controlled human infection models
  • experimental medicine
  • infectious disease
  • low-middle-income countries
  • mucosal immunology
  • vaccination

Fingerprint

Dive into the research topics of 'Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022'. Together they form a unique fingerprint.

Cite this